AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1681275 — intervention group
Group type: COMPARATOR
Intervention: Control group (no letters)
Number of subjects: 0
Study 6759285 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 480 mg daily
Number of subjects: 15
Study 6759285 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 60 mg daily
Number of subjects: 15
Study 6759285 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 31285414 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular injection of Tranexamic Acid (TXA) 1.5 g in 50 ml normal saline
Number of subjects: 101
Study 31285414 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 101
Study 28665556 — intervention group
Group type: COMPARATOR
Intervention: T-PEP
Number of subjects: 120
Study 28665556 — intervention group
Group type: COMPARATOR
Intervention: O-PEP
Number of subjects: 120
Study 27362791 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine-augmented CBT
Number of subjects: 39
Study 27362791 — intervention group
Group type: COMPARATOR
Intervention: Placebo-augmented CBT
Number of subjects: 39
Study 24131861 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal psychodynamic therapy
Number of subjects: 242
Study 24131861 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced cognitive behaviour therapy
Number of subjects: 242
Study 24131861 — intervention group
Group type: COMPARATOR
Intervention: Optimised treatment as usual
Number of subjects: 242
Study 20970283 — intervention group
Group type: EXPERIMENTAL
Intervention: GRACE score
Number of subjects: 2263
Study 20970283 — intervention group
Group type: EXPERIMENTAL
Intervention: TIMI score
Number of subjects: 2263
Study 20970283 — intervention group
Group type: EXPERIMENTAL
Intervention: Age alone
Number of subjects: 2263
Study 20970283 — intervention group
Group type: COMPARATOR
Intervention: Major adverse events
Number of subjects: 2263
Study 20555281 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm-up and stretch (WS)
Number of subjects: 30
Study 20555281 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching only (SO)
Number of subjects: 30
Study 20555281 — intervention group
Group type: COMPARATOR
Intervention: Control condition (CON)
Number of subjects: 30
Study 18635499 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 microg ultrapurified capsaicin (ALGRX 4975)
Number of subjects: 41
Study 18635499 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 16473229 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol/Fentanyl (P/F group)
Number of subjects: 30
Study 16473229 — intervention group
Group type: COMPARATOR
Intervention: Ketamine/Midazolam (K/M group)
Number of subjects: 30
Study 16473229 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 11994058 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine alone (8 mg)
Number of subjects: 8
Study 11994058 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine with quinidine (50 mg every 6 h for 2 days prior and during the study)
Number of subjects: 8
Study 11994058 — intervention group
Group type: COMPARATOR
Intervention: Chlorpheniramine alone
Number of subjects: 8
Study 10654755 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline cream applied twice daily to one thigh/buttock (placebo on the other)
Number of subjects: 52
Study 10654755 — intervention group
Group type: EXPERIMENTAL
Intervention: Endermologie treatment applied twice weekly to one thigh/buttock
Number of subjects: 52
Study 10654755 — intervention group
Group type: EXPERIMENTAL
Intervention: Endermologie treatment applied to both thighs/buttocks with the same cream regimen as group 1
Number of subjects: 52
Study 9121998 — intervention group
Group type: EXPERIMENTAL
Intervention: Before treatment (I)
Number of subjects: 14
Study 9121998 — intervention group
Group type: EXPERIMENTAL
Intervention: On the 3rd treatment week (II)
Number of subjects: 14
Study 9121998 — intervention group
Group type: EXPERIMENTAL
Intervention: After achievement of euthyroid (III)
Number of subjects: 14
Study 9121998 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 14
Study 1929772 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine hydrochloride (mean dose 120 +/- 48 mg/d)
Number of subjects: 25
Study 1929772 — intervention group
Group type: COMPARATOR
Intervention: Desipramine hydrochloride (mean dose 135 +/- 53 mg/d)
Number of subjects: 25
Study 6617219 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial catheter insertion
Number of subjects: 155
Study 6617219 — intervention group
Group type: COMPARATOR
Intervention: Femoral catheter insertion
Number of subjects: 155
Study 6617219 — intervention group
Group type: EXPERIMENTAL
Intervention: Both femoral and radial catheters
Number of subjects: 155
Study 29297147 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate variability biofeedback (HRV-BF)
Number of subjects: 210
Study 29297147 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 210
Study 27150263 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 kHz Interferential Current (IFC)
Number of subjects: 150
Study 27150263 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 kHz Interferential Current (IFC)
Number of subjects: 150
Study 27150263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 27150263 — intervention group
Group type: EXPERIMENTAL
Intervention: Active groups (1 kHz and 4 kHz)
Number of subjects: 150
Study 25283070 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented visual feedback training (VFT)
Number of subjects: 33
Study 25283070 — intervention group
Group type: COMPARATOR
Intervention: Conventional balance training (Control)
Number of subjects: 33
Study 22676430 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) provided by MSWs in clients' homes
Number of subjects: 0
Study 20374078 — intervention group
Group type: EXPERIMENTAL
Intervention: RimabotulinumtoxinB (BoNT‐B)
Number of subjects: 0
Study 17586596 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP testing
Number of subjects: 452
Study 17586596 — intervention group
Group type: COMPARATOR
Intervention: Standard assessment (control)
Number of subjects: 452
Study 16563240 — intervention group
Group type: EXPERIMENTAL
Intervention: EnSite-NavX system (group I, n = 40)
Number of subjects: 75
Study 16563240 — intervention group
Group type: COMPARATOR
Intervention: CARTO system (group II, n = 35)
Number of subjects: 75
Study 16563240 — intervention group
Group type: EXPERIMENTAL
Intervention: EnSite-NavX system (group I)
Number of subjects: 75
Study 16563240 — intervention group
Group type: COMPARATOR
Intervention: CARTO system (group II)
Number of subjects: 75
Study 12149503 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine (0.25 mg/kg twice a day over 18 months)
Number of subjects: 600
Study 12149503 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study 9495403 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback group
Number of subjects: 27
Study 7650070 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of 50 mg flurbiprofen
Number of subjects: 12
Study 7650070 — intervention group
Group type: COMPARATOR
Intervention: Single topical application of a 40 mg flurbiprofen patch
Number of subjects: 12
Study 7650070 — intervention group
Group type: COMPARATOR
Intervention: Repeated application of the topical patch (twice daily for 7 days)
Number of subjects: 12
Study 7650070 — intervention group
Group type: COMPARATOR
Intervention: Topical patch
Number of subjects: 12
Study 2745390 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine 1.5 mg/kg daily for 3 months
Number of subjects: 13
Study 2745390 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine
Number of subjects: 13
Study 2745390 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial HVA levels
Number of subjects: 13
Study 1115706 — intervention group
Group type: EXPERIMENTAL
Intervention: Backscatter from intense pulse light (10 light pulses from a Grimes '360 strobe')
Number of subjects: 20
Study 1115706 — intervention group
Group type: COMPARATOR
Intervention: No backscatter (no light pulses)
Number of subjects: 20
Study 31047901 — intervention group
Group type: EXPERIMENTAL
Intervention: Data-driven cluster analysis for selecting glucose-lowering therapy
Number of subjects: 4351
Study 31047901 — intervention group
Group type: COMPARATOR
Intervention: Simple clinical features (sex, BMI, age at diagnosis, baseline HbA1c)
Number of subjects: 4351
Study 31047901 — intervention group
Group type: COMPARATOR
Intervention: Age at diagnosis for glycaemic progression
Number of subjects: 4351
Study 31047901 — intervention group
Group type: COMPARATOR
Intervention: Estimated glomerular filtration rate at baseline
Number of subjects: 4351
Study 27474192 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrowband blue light (λmax 458‐480 nm, n = 23)
Number of subjects: 60
Study 27474192 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrowband green light (λmax 551‐555 nm, n = 25)
Number of subjects: 60
Study 27474192 — intervention group
Group type: COMPARATOR
Intervention: Darkness control (0 lux, n = 12)
Number of subjects: 60
Study 24445278 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg
Number of subjects: 1500
Study 23768260 — intervention group
Group type: EXPERIMENTAL
Intervention: Panic-focused psychodynamic psychotherapy (PFPP)
Number of subjects: 54
Study 23768260 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy (CBT) plus exposure therapy
Number of subjects: 54
Study 20202971 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan
Number of subjects: 21
Study 20202971 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan + Sildenafil
Number of subjects: 21
Study 19157318 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone (20-60 mg daily, tapered over 2 weeks)
Number of subjects: 45
Study 19157318 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone + TENS (10-30 mg daily, tapered over 2 weeks with TENS treatment)
Number of subjects: 45
Study 19157318 — intervention group
Group type: COMPARATOR
Intervention: TENS (low frequency 2 Hz for two weeks)
Number of subjects: 45
Study 16791665 — intervention group
Group type: COMPARATOR
Intervention: Saline 0.9%
Number of subjects: 67
Study 16791665 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloids (gelatin 4%, hydroxyethyl starch 6%, albumin 5%)
Number of subjects: 67
Study 12603405 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical cystectomy with urostomy
Number of subjects: 306
Study 12603405 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal population)
Number of subjects: 306
Study 10978264 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant hirudin
Number of subjects: 67
Study 10978264 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 67
Study 8817264 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal digital sensibility
Number of subjects: 0
Study 8817264 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthesia of the index finger and thumb
Number of subjects: 0
Study 8817264 — intervention group
Group type: EXPERIMENTAL
Intervention: Forearm-support condition
Number of subjects: 0
Study 8817264 — intervention group
Group type: EXPERIMENTAL
Intervention: No-support condition
Number of subjects: 0
Study 7930339 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (10 mg intravenous dose)
Number of subjects: 12
Study 3168338 — intervention group
Group type: EXPERIMENTAL
Intervention: Ionic amidotrizoate (370 mg/ml, osmolality 2.1 osmol/kg)
Number of subjects: 10
Study 3168338 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonionic iopamidol (370 mg/ml, osmolality 0.8 osmol/kg)
Number of subjects: 10
Study 3168338 — intervention group
Group type: COMPARATOR
Intervention: Both contrast media
Number of subjects: 10
Study 31286672 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutropenic diet
Number of subjects: 23
Study 28655900 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 24
Study 28655900 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 27194309 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral nutrition intervention
Number of subjects: 136
Study 23407696 — intervention group
Group type: EXPERIMENTAL
Intervention: Normothermic (NMTH) group (n = 20)
Number of subjects: 40
Study 23407696 — intervention group
Group type: COMPARATOR
Intervention: Hypothermic (HPTH) group (n = 20)
Number of subjects: 40
Study 21188414 — intervention group
Group type: EXPERIMENTAL
Intervention: Clicking task with low mental load
Number of subjects: 43
Study 21188414 — intervention group
Group type: EXPERIMENTAL
Intervention: Clicking task with high mental load (mental arithmetic)
Number of subjects: 43
Study 21188414 — intervention group
Group type: COMPARATOR
Intervention: Rest condition
Number of subjects: 43
Study 20002085 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg voriconazole orally
Number of subjects: 20
Study 20002085 — intervention group
Group type: COMPARATOR
Intervention: 400 mg voriconazole intravenously
Number of subjects: 20
Study 20002085 — intervention group
Group type: EXPERIMENTAL
Intervention: Both routes of administration
Number of subjects: 20
Study 16894074 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV intervention
Number of subjects: 553
Study 16894074 — intervention group
Group type: COMPARATOR
Intervention: Health‐promotion intervention
Number of subjects: 553
Study 14750014 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensorimotor training
Number of subjects: 0
Study 14750014 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 0
Study 14750014 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 11707792 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal needles inserted into painful points
Number of subjects: 70
Study 11707792 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (needles inserted into nonpainful points)
Number of subjects: 70
Study 11707792 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 70
Study 8646220 — intervention group
Group type: EXPERIMENTAL
Intervention: SLE patients
Number of subjects: 25
Study 8646220 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 25
Study 15374366 — intervention group
Group type: EXPERIMENTAL
Intervention: Idebenone (CV-2619) 90 mg/daily
Number of subjects: 104
Study 15374366 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 6376128 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cis-platinum (100 mg/m2) + adriamycin (60 mg/m2)
Number of subjects: 22
Study 6376128 — intervention group
Group type: COMPARATOR
Intervention: Adriamycin (60 mg/m2) + cis-platinum (60 mg/m2)
Number of subjects: 22
Study 30684199 — intervention group
Group type: EXPERIMENTAL
Intervention: FIT return in year 1
Number of subjects: 5195
Study 30684199 — intervention group
Group type: EXPERIMENTAL
Intervention: FIT return in year 2
Number of subjects: 5195
Study 30684199 — intervention group
Group type: EXPERIMENTAL
Intervention: FIT return among year 1 adherers in year 2
Number of subjects: 5195
Study 30684199 — intervention group
Group type: EXPERIMENTAL
Intervention: FIT return among year 1 non-adherers in year 2
Number of subjects: 5195
Study 30684199 — intervention group
Group type: COMPARATOR
Intervention: Comparison of year 1 adherers vs non-adherers in year 2
Number of subjects: 5195
Study 30684199 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with higher odds of FIT return
Number of subjects: 5195
Study 30684199 — intervention group
Group type: EXPERIMENTAL
Intervention: Neighborhood factor associated with lower FIT return
Number of subjects: 5195
Study 29421687 — intervention group
Group type: EXPERIMENTAL
Intervention: 2017 ACC/AHA hypertension guidelines (systolic BP ≥130 mm Hg or diastolic BP ≥80 mm Hg)
Number of subjects: 4683
Study 29421687 — intervention group
Group type: COMPARATOR
Intervention: JNC 7 hypertension guidelines (systolic BP ≥140 mm Hg or diastolic BP ≥90 mm Hg)
Number of subjects: 4683
Study 29421687 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of newly reclassified hypertension vs prior guidelines
Number of subjects: 4683
Study 26401858 — intervention group
Group type: EXPERIMENTAL
Intervention: Local levobupivacaine infiltration (20 mL of levobupivacaine 0.25%)
Number of subjects: 60
Study 26401858 — intervention group
Group type: COMPARATOR
Intervention: Intravenous paracetamol (1g before extubation and 5g in the 24 postoperative period)
Number of subjects: 60
Study 26401858 — intervention group
Group type: COMPARATOR
Intervention: Intravenous lornoxicam (8 mg before extubation and 8 mg in the 24 postoperative period)
Number of subjects: 60
Study 23969907 — intervention group
Group type: EXPERIMENTAL
Intervention: Anorganic bone matrix/cell binding peptide (ABM/P‐15)
Number of subjects: 15
Study 23969907 — intervention group
Group type: COMPARATOR
Intervention: Guided tissue regeneration (GTR)
Number of subjects: 15
Study 22480189 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT and Dextroamphetamine
Number of subjects: 48
Study 22480189 — intervention group
Group type: COMPARATOR
Intervention: CBT and placebo
Number of subjects: 48
Study 19195665 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (r-hGH)
Number of subjects: 42
Study 19195665 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 42
Study 17404779 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (3mg) administered one hour before bedtime for four weeks
Number of subjects: 18
Study 17404779 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered one hour before bedtime for four weeks
Number of subjects: 18
Study 17404779 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (3mg)
Number of subjects: 18
Study 15161116 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone acetate injection
Number of subjects: 60
Study 15161116 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone (10-day course)
Number of subjects: 60
Study 11498721 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cocaine (62.5, 125, 250 mg/70 kg)
Number of subjects: 0
Study 11498721 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cocaine (12.5, 25, 50 mg/70 kg)
Number of subjects: 0
Study 11498721 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cocaine
Number of subjects: 0
Study 11498721 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cocaine
Number of subjects: 0
Study 11498721 — intervention group
Group type: COMPARATOR
Intervention: Both oral and intravenous cocaine
Number of subjects: 0
Study 9919334 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT-11 (irinotecan hydrochloride) at a dose of 120 mg/m2 i.v. over 4 hours on days 1 and 15, and mitomycin-C (MMC) at a dose of 7 mg/m2 i.v. as a bolus on days 1 and 15, given for at least 2 cycles, 4 weeks apart.
Number of subjects: 25
Study 9114186 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral azithromycin (20 mg/kg) administered as a single dose, one dose a week for 3 weeks, or one dose every 4 weeks for a total of six doses
Number of subjects: 168
Study 9114186 — intervention group
Group type: COMPARATOR
Intervention: Topical oxytetracycline/polymyxin eye ointment (once daily for 5 days every 4 weeks; total of six treatment cycles)
Number of subjects: 168
Study 2667325 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methotrexate pretreatment at 0 h before 5-FU
Number of subjects: 32
Study 2667325 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methotrexate pretreatment at 3 h before 5-FU
Number of subjects: 32
Study 2667325 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methotrexate followed by 5-FU (both doses: 1,000 mg/m2)
Number of subjects: 32
Study 8814 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine (CPZ) treatment after placebo
Number of subjects: 18
Study 8814 — intervention group
Group type: COMPARATOR
Intervention: Acute CPZ treatment
Number of subjects: 18
Study 8814 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 31772083 — intervention group
Group type: EXPERIMENTAL
Intervention: Atosiban
Number of subjects: 1514
Study 31772083 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1514
Study 27657350 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic field therapy (MFT)
Number of subjects: 44
Study 27657350 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 25024135 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimalist shoe
Number of subjects: 18
Study 25024135 — intervention group
Group type: COMPARATOR
Intervention: Standard shoe
Number of subjects: 18
Study 24259042 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with acute heart failure
Number of subjects: 2033
Study 24259042 — intervention group
Group type: COMPARATOR
Intervention: Men with acute heart failure
Number of subjects: 2033
Study 21975668 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) 0.14 mg/kg/d for 4 months
Number of subjects: 14
Study 21975668 — intervention group
Group type: COMPARATOR
Intervention: Control group (CTR) without GH for 4 months, followed by GH for 4 months
Number of subjects: 14
Study 21975668 — intervention group
Group type: COMPARATOR
Intervention: Control group (CTR) after GH treatment
Number of subjects: 14
Study 21975668 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) after discontinuation
Number of subjects: 14
Study 21975668 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 14
Study 19571282 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (20 mg daily)
Number of subjects: 285
Study 19571282 — intervention group
Group type: COMPARATOR
Intervention: Losartan (100 mg daily)
Number of subjects: 285
Study 19571282 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 285
Study 17078448 — intervention group
Group type: EXPERIMENTAL
Intervention: He‐Ne laser auricular irradiation plus body acupuncture
Number of subjects: 68
Study 17078448 — intervention group
Group type: COMPARATOR
Intervention: Body acupuncture only
Number of subjects: 68
Study 14769732 — intervention group
Group type: EXPERIMENTAL
Intervention: tgAAVCF
Number of subjects: 42
Study 14769732 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 11301406 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin 20 mg/kg/day p.o. every 12 hours for 6 days
Number of subjects: 87